Clinical Trial Update: Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating APL180 on endothelial function in familial hypercholesterolemia patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• APL180

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Familial Hypercholesterolemia | Phase 2 | Status: WITHDRAWN